Infection, Bacterial, Surgical Incision, Surgical Wound, Wound Infection, Wound Infection, Surgical
Conditions
Keywords
Infection, Surgical Site Infection, Dialkylcarbamoylchloride
Brief summary
Surgical site infection is an infection at a place in the body where surgery has taken place, and has been reported in around 5% of people undergoing an operation. In vascular surgery, infection rates are as high as 30%. Methods to reduce this rate of infection should be investigated thoroughly for their effectiveness and cost-effectiveness. The investigators aim to conduct a research trial examining one such method. Leukomed Sorbact is a wound dressing coated with a chemical (DACC) derived from spider-silk that interacts with, and binds bacteria, causing them to be mechanically removed from a wound when the dressing is changed. The trial aims to compare the effectiveness of this dressing to a standard, non-coated dressing, in the reduction of surgical site infection. 718 patients from a number of centres across the UK will be recruited to this study. Adult patients who are having a vascular surgery operation will be approached for entry into the trial. The trial will be explained to them, as well as an explanation that participation is voluntary and their operation or other aspects of their care will not be impacted in any way should participants not wish to participate. Participants will be randomised by computer into one of two groups - one group whose wounds are dressed with Leukomed Sorbact, and the other whose wounds are dressed with a standard dressing. Patients will be followed up at 30 days post-operatively. At the follow up, their wounds will be inspected for infection, and participants will be asked to complete short questionnaires measuring quality of life. Quality of life will also be assessed at 3 months post surgery. The trial will aim to answer a number of questions, with the primary question being does a DACC coated dressing applied after an operation reduce the risk of an infection at the surgery site? It will also ask whether this treatment is cost-effective and whether it promotes satisfactory healing and evaluate the overall carbon footprint impact of each intervention. Studies Within a Trial will be conducted to validate a remote diagnostic measure for detecting surgical site infection using wound images and the Bluebelle Wound Healing Questionnaire, evaluate feasibility of novel hair removal methods such as epilation and waxing, carbon footprint modelling within randomised controlled trials.
Interventions
DEVICEDACC-Coated Post Operative Dressing
Leukomed Sorbact is a non-active coated wound dressing, containing Dialkylcarbomoylchloride. This is a bacteria-binding compound that adheres bacteria via hydrophobic interaction and removes them from the wound bed at dressing change.
Sponsors
Hull University Teaching Hospitals NHS Trust
University of Hull
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
In order to be eligible for inclusion in the study the participants must meet the following criteria: * Adults ≥18 yrs undergoing clean or clean-contaminated lower limb vascular surgery, with wounds closed by primary intention. * Able to understand the Patient Information Sheet and supplementary materials and capable and willing to give informed consent and follow the protocol requirements (including attending all follow-up visits and completing written questionnaires).
Exclusion criteria
Patients will not be included in the study if they meet any of the following
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 30 day infection rate | 30 days | Surgical Site Infection at 30 days post-op |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 3 month infection rate | 3 months | Surgical Site Infection at 3 months post-op (implant patients only) |
| Quality of Life (SF-36 V2) | 30 days, 3 months | Score ranging from 0-100, higher values indicating better health |
| Quality of Life (EQ-5D-3L) | 30 days, 3 months | Score ranging from 5-15, higher scores indicating worse health |
| Mortality | 30 days | 30-day mortality |
| Bluebelle wound healing questionnaire | Days 30 and 37 | Score ranging 0-41, higher values indicating infection |
| Carbon Footprint Analysis | 3 months | Healthcare resource use data |
Countries
United Kingdom
Contacts
PRINCIPAL_INVESTIGATORGeorge Smith, M.D
Hull University Teaching Hospitals NHS Trust
Outcome results
None listed